A medical device that works inside the digestive tract needs more than a clever sensor. If it uses electricity, someone must also solve the problem of powering it—and decide what should happen to its components afterwards.
A bioresorbable battery described on 21 September 2026 offers one experimental answer. Researchers led by MIT developed a small power source using magnesium and molybdenum trioxide, with materials designed to break down over time. Their paper in Nature Chemical Engineering reports tests of capsule-scale electronics in pigs. This is preclinical research, with no demonstrated treatment benefit in people. The research paper
The attraction is a device with a useful working life and a planned ending. Temporary electronics could perform a task without leaving a conventional battery to remain intact indefinitely.
What the battery actually powered
The researchers demonstrated two uses: assisting a radio-frequency identification tag and supplying electrical stimulation inside the stomach. The battery reached a peak open-circuit voltage of 1.84 volts. That voltage is a component measurement, not a claim about the effectiveness of any treatment. Study abstract
MIT reports that the radio tag transmitted from within the gastrointestinal tract over distances of up to 1.5 metres in animal tests. A separate device delivered stimulation intended to influence ghrelin, a hormone involved in appetite. In those tests, 20 minutes of stimulation increased ghrelin levels by about 50%. MIT’s account
A hormone change is an early biological result. It does not establish that the device treats appetite loss, improves nutrition or helps patients recover. Those are different outcomes requiring clinical evidence.
“Dissolving” needs careful interpretation
Bioresorbable means materials can be broken down and absorbed. The engineering challenge is controlling that process while preserving enough power for the intended task.
The paper’s degradation experiments included both physiological-temperature conditions and accelerated testing at higher temperature. It would therefore be misleading to turn a laboratory breakdown timeline into a promise about exactly when a complete device disappears inside a person. Degradation methods and results
MIT also notes that the stimulation prototype was not entirely bioresorbable: a printed circuit board remained. Battery chemistry, protective layers and the rest of the electronics each matter. Prototype limitations
That detail makes the achievement more specific and useful. The team has addressed an important power component, without claiming that every part of every future capsule has been solved.
A component that could open more doors
Our view is that the platform may ultimately matter more than either demonstration. A dependable temporary power source could give device designers more freedom to choose sensors, communication systems and operating windows.
The next convincing milestones would include reproducible manufacturing, predictable operation and breakdown, and carefully monitored human studies. Success would also need to be judged against simpler approaches that do not require powered electronics.
This is part of a broader effort to place very small technologies close to biological processes, including wireless devices being explored in cancer research. The applications and evidence are different, but both show why the interface between engineering and living tissue matters.
For now, MIT has demonstrated that this battery can do useful work in an animal model. That is a meaningful step towards temporary medical electronics, with the clinical questions still open.
Featured image: Conventional medicine capsules, shown for context. The photograph does not depict MIT’s experimental battery or an approved ingestible electronic device. Image: Christina Victoria Craft / Unsplash.
Leave a Reply